FMR LLC reduced its position in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 21.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,782,447 shares of the biotechnology company’s stock after selling 751,956 shares during the period. FMR LLC owned approximately 9.64% of Atara Biotherapeutics worth $39,512,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in ATRA. Creative Planning purchased a new stake in shares of Atara Biotherapeutics during the third quarter worth about $213,000. Eagle Asset Management Inc. increased its stake in shares of Atara Biotherapeutics by 0.8% in the third quarter. Eagle Asset Management Inc. now owns 980,673 shares of the biotechnology company’s stock worth $20,976,000 after buying an additional 8,081 shares during the last quarter. Neuberger Berman Group LLC increased its stake in shares of Atara Biotherapeutics by 9.5% in the third quarter. Neuberger Berman Group LLC now owns 688,715 shares of the biotechnology company’s stock worth $14,732,000 after buying an additional 59,595 shares during the last quarter. Alps Advisors Inc. purchased a new stake in shares of Atara Biotherapeutics during the third quarter worth about $786,000. Finally, BlackRock Inc. increased its stake in shares of Atara Biotherapeutics by 108.1% in the third quarter. BlackRock Inc. now owns 12,697 shares of the biotechnology company’s stock worth $272,000 after buying an additional 6,597 shares during the last quarter. 77.48% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) traded down 10.58% during midday trading on Friday, reaching $16.90. 756,366 shares of the company were exchanged. The stock’s market capitalization is $491.60 million. Atara Biotherapeutics Inc has a 12-month low of $12.45 and a 12-month high of $25.73. The company has a 50 day moving average price of $19.06 and a 200-day moving average price of $16.90.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, March 9th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.98) by $0.35. On average, analysts forecast that Atara Biotherapeutics Inc will post ($3.62) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Fmr LLC Has $39.512 Million Position in Atara Biotherapeutics Inc (ATRA)” was published by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://baseballnewssource.com/markets/fmr-llc-has-39512000-stake-in-atara-biotherapeutics-inc-atra-updated-updated/525596.html.
ATRA has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 4th. Canaccord Genuity set a $47.00 target price on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research note on Wednesday, January 18th. Finally, Citigroup Inc set a $10.00 target price on shares of Atara Biotherapeutics and gave the company a “sell” rating in a research note on Thursday, March 16th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Atara Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $24.00.
In related news, CFO John Mcgrath sold 14,000 shares of the company’s stock in a transaction dated Thursday, March 23rd. The stock was sold at an average price of $20.65, for a total value of $289,100.00. Following the completion of the sale, the chief financial officer now directly owns 119,327 shares of the company’s stock, valued at approximately $2,464,102.55. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Isaac E. Ciechanover sold 4,800 shares of the company’s stock in a transaction dated Friday, February 3rd. The shares were sold at an average price of $13.66, for a total value of $65,568.00. Following the completion of the sale, the chief executive officer now directly owns 555,044 shares of the company’s stock, valued at $7,581,901.04. The disclosure for this sale can be found here. Insiders have sold a total of 151,195 shares of company stock valued at $2,738,542 over the last three months. 16.10% of the stock is currently owned by insiders.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with our FREE daily email newsletter.